Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
Fuente:
Zenodo
Saved in:
Bibliographic Details
Main Author:
Posch, Wilfried
Format:
Recurso digital
Published:
Zenodo
2022
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://doi.org/10.5281/zenodo.19388258
Similar Items
SARS‐COV‐2 Pre‐Exposure Prophylaxis With Tixagevimab‐Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era
by: Manuela A. Hoechstetter, et al.
Published: (2025)
SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
by: Christopher A. Reis, et al.
Published: (2024)
Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect
by: Jing Zhang, et al.
Published: (2025)
Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults
by: Nanyang Li, et al.
Published: (2025)
Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS‐CoV‐2 Variants: A Case Report Study with Comparison to a Vaccinated Population
by: Constant Gillot, et al.
Published: (2024)